Milestone Reached In NeuroVive-Sihuan Collaboration

NeuroVive Pharmaceutical Asia Ltd. has received the first milestone payment from Sihuan Pharmaceutical, the company’s collaboration partner in China.

AsianScientist (Jun. 18, 2013) – NeuroVive Pharmaceutical Asia Ltd. has received the first milestone payment from Sihuan Pharmaceutical, the company’s collaboration partner in China. The collaboration involves the distribution of NuroVive’s CicloMulsion® and NeuroSTAT® products in the Chinese market.

CicloMulsion® is the first cyclophilin inhibitor developed for the treatment of reperfusion injury while NeuroSTAT® is being developed for the treatment of patients with traumatic brain injury.

“The first payment from Sihuan shows that our work in China has been successful so far, and that our collaboration partner is delivering on its promises,” said Mikael Brönnegård, CEO of NeuroVive Pharmaceutical AB, the parent company of NeuroVive Pharmaceutical Asia Ltd.

The collaboration partners are also completing an application to the Chinese healthcare regulation agency (CFDA) for a clinical trial using CicloMulsion® in China.

——

Source: NeuroVive.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Asian Scientist Magazine is an award-winning science and technology magazine that highlights R&D news stories from Asia to a global audience. The magazine is published by Singapore-headquartered Wildtype Media Group.

Related Stories from Asian Scientist